Targeting Transforming Growth Factor-β TGF-β in Cancer and Non-Neoplastic DiseasesReportar como inadecuado

Targeting Transforming Growth Factor-β TGF-β in Cancer and Non-Neoplastic Diseases - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Transforming growthfactor-β TGF-βsuperfamily is a key player in the regulation of a wide variety ofphysiological processes from development to pathogenesis. Since the discoveryof the prototypic member, TGF-β, almost three decades ago, there havebeen tremendous advances in our understanding of its complex biology. TGF-β misregulation has been implicated inthe pathogenesis of a variety of diseases, including cancer with a direct rolein facilitating metastasis, fibrosis and inflammation. Consequently, TGF-β is currently explored as a prognosticcandidate biomarker of tumor invasiveness and metastasis; and it offers anattractive target for cancer therapy. Several anti-TGF-β approaches, such as TGF-β antibodies, antisense oligonucleotidesand small molecules inhibitors of TGF-β type 1 receptor kinase, have showngreat promise in the preclinical studies. Here, we consider why the TGF-βsignalingpathway is a drug target, the potential clinical applications of TGF-β inhibition, the issues arising withanti-TGF-β therapy and howthese might be adopted using personalized approaches with a special care forpatient selection and timing of therapy so that we may bring forward all thepotentials of targeting this pathway for therapeutic uses in both cancer,preferentially in combination therapy, and non-neoplastic diseases.


Transforming Growth Factor-β TGF-β, Monoclonal Antibodies MoAbs, Antisense Oligonucleotides ASO, Small Molecule Receptor Kinase Inhibitors SMIs

Cite this paper

Nacif, M. and Shaker, O. 2014 Targeting Transforming Growth Factor-β TGF-β in Cancer and Non-Neoplastic Diseases. Journal of Cancer Therapy, 5, 735-747. doi: 10.4236-jct.2014.57082.

Autor: Michael Nacif, Olfat Shaker



Documentos relacionados